-+ 0.00%
-+ 0.00%
-+ 0.00%

Precision Peptide Says HHS Draft Policy Aligns With Needle-Free Strategy

PUBT·11/03/2026 12:09:53
Listen to the news
Precision Peptide Says HHS Draft Policy Aligns With Needle-Free Strategy
  • Precision Peptide is evaluating how HHS's draft peptide compounding policy may apply to its US prescription formulary with its compounding partner.
  • The October 30, 2026, draft outlines a potential interim pathway for six peptides, recognizing non-injectable routes for three, including BPC-157.
  • Conditions include FDA-registered sourcing, lot-level certificates of analysis and safety reporting.
  • The framework aligns with its needle-free strategy; its US formulary reached 16 prescription therapies on October 29, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611030700NEWSFILECNPR____20261103_322210_1) on November 03, 2026, and is solely responsible for the information contained therein.